文献速递生殖医学妇科

解码卵巢衰老的免疫调控:机制与治疗策略

Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.
PubMed 文献 · Hum Reprod Update · 2026-10-09

本文综述了免疫系统在卵巢衰老中的作用,涵盖生理性衰老与早发性卵巢功能不全(POI)的免疫机制。系统性免疫衰老与慢性低度炎症通过免疫-卵巢轴驱动卵泡耗竭和功能障碍,免疫调节策略有望延缓卵巢衰老。

要点

  • 免疫细胞与细胞因子网络构成调控卵泡发育、排卵和黄体功能的免疫-卵巢轴。
  • 衰老卵巢局部存在慢性炎症、NLRP3炎症小体激活及衰老细胞积累。
  • POI兼具与生理衰老共享的炎症特征及自身免疫相关特异性免疫异常。

核心结论

  • 免疫失调是卵巢衰老的机制驱动因素而非次要相关因素。
  • 将卵巢衰老重新定义为可修饰的免疫介导过程,为延长生殖寿命提供新机会。

研究设计与样本

  • 综述类文章,检索PubMed截至2026年4月的原创文章,使用「免疫系统」「卵巢功能」「炎症」「免疫细胞」「卵巢衰老」「绝经」「早发性卵巢功能不全」「治疗」等术语组合。

主要发现

  • 免疫细胞和细胞因子网络调控卵泡发生、排卵和黄体动态。
  • 绝经过渡期加速免疫衰老并放大促炎细胞因子产生。
  • 衰老卵巢表现出慢性炎症、NLRP3炎症小体激活和衰老相关分泌表型细胞积累。
  • 衰老卵巢中组织驻留巨噬细胞向单核细胞来源巨噬细胞转变,炎性γδ和双阴性T细胞扩增。
  • POI以自身免疫共病、B细胞驱动的体液异常、T细胞失调和影响免疫通路的遗传变异为特征。

临床怎么用

  • 将免疫生物标志物整合到预测框架中,并设计分层免疫调节试验。
  • 卵巢衰老管理可能从症状性激素替代转向基于机制的干预。

局限性

  • 多种免疫调节策略尚处于早期临床评估阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ovarian aging is among the earliest functional declines in humans and acts as a pacemaker of female aging. It encompasses both physiological age-related ovarian decline and pathological accelerated aging, exemplified by premature ovarian insufficiency (POI). Increasing evidence positions the immune system as both a regulator of ovarian homeostasis and a driver of ovarian dysfunction. Age-related immunosenescence and chronic low-grade inflammation (inflammaging) coordinately drive ovarian aging through bidirectional crosstalk between systemic immunity and the ovarian immune microenvironment. POI frequently coexists with autoimmune disorders, reinforcing the central role of the immune-ovarian axis in reproductive aging. Elucidating this interplay may enable targeted immunomodulatory strategies to preserve reproductive longevity and mitigate systemic consequences of ovarian decline. OBJECTIVE AND RATIONALE: The aim was to synthesize current evidence on (i) immune regulation of normal ovarian physiology; (ii) immune alterations in physiological ovarian aging, including systemic immunosenescence and ovarian immune microenvironment remodelling; (iii) autoimmune dysregulation in POI; and (iv) the translational potential of immunomodulatory interventions for mitigating ovarian aging. SEARCH METHODS: Original articles published up to April 2026 were identified through PubMed using combinations of the terms 'immune system', 'ovarian function', 'inflammation', 'immune cell', 'ovarian aging', 'menopause', 'primary ovarian insufficiency', and 'therapeutics'. OUTCOMES: Immune cells and cytokine networks form a specialized regulatory axis that governs folliculogenesis, ovulation, and luteal dynamics. This review synthesizes emerging evidence showing that this immune-ovary axis undergoes profound remodelling during reproductive aging and that immune dysregulation is a causal driver of ovarian functional decline. Systemically, the menopausal transition accelerates immunosenescence and amplifies pro-inflammatory cytokine production. Locally, the aging ovary exhibits chronic inflammation, NLRP3 inflammasome activation, and accumulation of senescent cells with a senescence‑associated secretory phenotype. These changes coincide with a shift from tissue‑resident to monocyte‑derived macrophages and expansion of inflammatory γδ and double‑negative T cells. This progressive loss of immune homeostasis promotes follicular depletion, stromal fibrosis, and impaired steroidogenesis. POI represents a pathological extreme of this axis, characterized by autoimmune comorbidities, B cell-driven humoural abnormalities, T cell dysregulation, and genetic variants affecting immune pathways. Comparative analysis reveals both conserved inflammatory signatures shared with physiological aging and POI-specific immune features that reflect overt immune-mediated ovarian injury. By integrating systemic, local, and disease-specific immune mechanisms, this review reframes ovarian aging as a modifiable immunological process. Therapeutically, emerging immunomodulatory strategies range from molecular agents targeting inflammatory mediators and senescence programs, through cell-based immune reprogramming with stem cells, regulatory T cells, and senolytic immune effectors, to lifestyle-driven systemic immunomodulation. These strategies show promise in restoring ovarian immune homeostasis and extending the reproductive lifespan, with several of these approaches now advancing toward early-phase clinical evaluation. WIDER IMPLICATIONS: Collectively, the current evidence positions immune dysregulation as a mechanistic driver, rather than a secondary correlate, of ovarian aging. Integrating immune biomarkers into predictive frameworks and designing stratified immunomodulatory trials may shift ovarian aging management from symptomatic hormone replacement toward mechanism-based intervention. Reframing ovarian aging as a modifiable immune-mediated process offers new opportunities to extend female reproductive longevity and the female health span. REGISTRATION NUMBER: N/A.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Wang C, Li N, Chen ZJ, et al. Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies. Hum Reprod Update. 2026. PMID: 42854090. doi:10.1093/humupd/dmag030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。